4.7 Review

Bruton's Tyrosine Kinase and Its Isoforms in Cancer

Journal

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.668996

Keywords

cancer; BTK; PI3K; kinase inhibitor; metastasis

Funding

  1. Research Foundation for the State University of New York [69344]
  2. Capital Region Medical Research Institute

Ask authors/readers for more resources

BTK is a soluble tyrosine kinase with important roles in B cells and epithelial cancers. Inhibition of BTK has been approved by the FDA for treating multiple malignancies, showing promising therapeutic potential.
Bruton's tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. BTK has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies. Targeting BTK with recently developed BTK inhibitors has been approved by the Food and Drug Administration (FDA) for the treatment of several hematological malignancies and has transformed the treatment of several B-cell malignancies. The roles that BTK plays in B cells have been appreciated for some time. Recent studies have established that BTK is expressed and plays pro-tumorigenic roles in several epithelial cancers. In this review, we focus on novel isoforms of the BTK protein expressed in epithelial cancers. We review recent work on the expression, function, and signaling of these isoforms and their value as potential therapeutic targets in epithelial tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available